BR112022015969A2 - Composições e métodos para enxerto de células editadas de base - Google Patents

Composições e métodos para enxerto de células editadas de base

Info

Publication number
BR112022015969A2
BR112022015969A2 BR112022015969A BR112022015969A BR112022015969A2 BR 112022015969 A2 BR112022015969 A2 BR 112022015969A2 BR 112022015969 A BR112022015969 A BR 112022015969A BR 112022015969 A BR112022015969 A BR 112022015969A BR 112022015969 A2 BR112022015969 A2 BR 112022015969A2
Authority
BR
Brazil
Prior art keywords
methods
compositions
graftting
base cells
edited base
Prior art date
Application number
BR112022015969A
Other languages
English (en)
Inventor
Smith Sarah
Levasseur Dana
Yen Jonathan
Original Assignee
Beam Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beam Therapeutics Inc filed Critical Beam Therapeutics Inc
Publication of BR112022015969A2 publication Critical patent/BR112022015969A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04004—Adenosine deaminase (3.5.4.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Developmental Biology & Embryology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

COMPOSIÇÕES E MÉTODOS PARA ENXERTO DE CÉLULAS EDITADAS DE BASE. A invenção fornece composições compreendendo novos editores de base de adenosina (por exemplo, ABE8) que aumentaram eficiência e os métodos de uso dessas variantes de adenosina desaminase para editar uma sequência alvo e os métodos de uso das mesmas para tratar distúrbios ou condições genéticas, por exemplo, doença falciforme, com enxerto.
BR112022015969A 2020-02-13 2021-02-12 Composições e métodos para enxerto de células editadas de base BR112022015969A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062976239P 2020-02-13 2020-02-13
PCT/US2021/017989 WO2021163587A1 (en) 2020-02-13 2021-02-12 Compositions and methods for engraftment of base edited cells

Publications (1)

Publication Number Publication Date
BR112022015969A2 true BR112022015969A2 (pt) 2022-10-25

Family

ID=77291886

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022015969A BR112022015969A2 (pt) 2020-02-13 2021-02-12 Composições e métodos para enxerto de células editadas de base

Country Status (7)

Country Link
US (1) US20230242884A1 (pt)
EP (1) EP4103704A1 (pt)
CN (1) CN116113692A (pt)
AU (1) AU2021218811A1 (pt)
BR (1) BR112022015969A2 (pt)
CA (1) CA3170326A1 (pt)
WO (1) WO2021163587A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116497067A (zh) 2019-02-13 2023-07-28 比姆医疗股份有限公司 治疗血红素病变的组合物和方法
CN110982820A (zh) * 2020-01-03 2020-04-10 云南中烟工业有限责任公司 一种烟草单倍体的基因编辑方法
WO2022232839A1 (en) * 2021-04-30 2022-11-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for improved production of primary cd34+ cells
EP4337701A1 (en) 2021-05-10 2024-03-20 Mammoth Biosciences, Inc. Effector proteins and methods of use
WO2023056139A1 (en) * 2021-10-01 2023-04-06 The Regents Of The University Of California Compositions and methods for treating a β-thalassemia disease
WO2024073606A1 (en) * 2022-09-28 2024-04-04 Regeneron Pharmaceuticals, Inc. Antibody resistant modified receptors to enhance cell-based therapies
CN117965505A (zh) * 2023-06-28 2024-05-03 微光基因(苏州)有限公司 工程化的腺苷脱氨酶及碱基编辑器

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017306676B2 (en) * 2016-08-03 2024-02-22 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
JP2020521446A (ja) * 2017-05-25 2020-07-27 ザ ジェネラル ホスピタル コーポレイション 二部塩基エディター（ｂｂｅ）構造およびｉｉ型−ｃ−ｃａｓ９ジンクフィンガー編集
EP3765614A1 (en) * 2018-03-14 2021-01-20 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
WO2019217942A1 (en) * 2018-05-11 2019-11-14 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
KR20210041008A (ko) * 2018-08-03 2021-04-14 빔 테라퓨틱스, 인크. 핵산 표적 서열을 변형시키기 위한 다중-이펙터 핵염기 편집기 및 이를 이용하는 방법

Also Published As

Publication number Publication date
EP4103704A1 (en) 2022-12-21
CA3170326A1 (en) 2021-08-19
CN116113692A (zh) 2023-05-12
WO2021163587A1 (en) 2021-08-19
US20230242884A1 (en) 2023-08-03
AU2021218811A1 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
BR112022015969A2 (pt) Composições e métodos para enxerto de células editadas de base
BR112022000641A2 (pt) Modificação genética de célula efetora imune e uso da mesma
BR112021006844A8 (pt) Métodos para editar um rna alvo e para tratar ou prevenir uma doença ou condição, rna editado ou uma célula hospedeira tendo um rna editado, rna que recruta desaminase, construção, biblioteca, composição, célula hospedeira, e, kit para editar um rna alvo .
CO2020001113A2 (es) Muteínas de interleucina 21 y métodos de tratamiento
BR112021020608A2 (pt) Rna recrutador de desaminase, construção, método para editar um rna alvo em uma célula hospedeira, e, construção, composição, célula, biblioteca ou kit
BR112023001641A2 (pt) Composições de edição dependentes de adar e métodos de uso das mesmas
BR112017010490A2 (pt) roedor, polipeptídeo cd47, célula ou tecido de roedor isolado, célula-tronco emprionária de roedor, embrião de roedor, e, métodos de produzir um roedor, de fornecimento de um roedor, de enxerto de células humanas em um roedor, de avaliação de eficácia terapêutica de uma droga direcionada a células humanas e de avaliar as propriedades farmacocinéticas, de avaliar a toxicidade específica e inespecífica de uma droga direcionada ao cd47 humano.
BR112022011235A2 (pt) Bibliotecas de variantes de ácido nucleico para receptores de adenosina
CL2022001145A1 (es) Composiciones y métodos para el reemplazo de alelos de adn codificado por arn
CO2018004763A2 (es) Edición genómica multiplexada
BR112021022917A2 (pt) Biomateriais compósitos
BR112018011242A2 (pt) métodos para modificação genética de plantas
BR9915191A (pt) Métodos para obter um polinucleotìdeo isolado epara produzir uma célula recombinante,protoplasto de célula vegetal, coleção deprotoplastos de célula vegetal, vegetal,polinucleotìdeo, biblioteca, um ou mais membros debiblioteca e célula recombinante alvo
CY1120496T1 (el) Μεθοδος για τη δημιουργια ενος ζωου ομοζυγου για μια γενετικη τροποποιηση
PE20110358A1 (es) Metodos y composiciones para el tratamiento de defectos oseos con poblaciones de celulas placentarias
BR112022021445A2 (pt) Métodos e composições para tratar condições inflamatórias associadas com doença infecciosa
CO2019004006A2 (es) Método para incrementar los niveles de secreción de la interleucina 2 y sus proteínas derivadas
AR050299A1 (es) Plantas con una enzima fosforilante del almidon con una actividad aumentada en plástidos.
BR112015027996A2 (pt) organoides compreendendo células renais isoladas e suas utilizações
AR021139A1 (es) Acidos nucleicos y polipeptidos de activadores de la transcripcion y metodos de uso de los mismos
BR112023020167A2 (pt) Fusões agente-ligante de ligação biespecífica para a degradação de proteínas alvo
CL2023000554A1 (es) Proteínas diseñadas y métodos de uso de las mismas.
BR112023001642A2 (pt) Bancos de células t específicos de antígeno universais e métodos de preparar e usar os mesmos automaticamente
BR112022008468A2 (pt) Método para modificação direcionada de uma sequência de genoma de planta
CL2022002276A1 (es) Composiciones y métodos para tratar discapacidad auditiva no asociada con la edad en un sujeto